CSTL - NASDAQ
Castle Biosciences, Inc.
$20.39
+3.4%Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
At a Glance
Live Snapshotcstl
Total Current Liabilities
Last Annual Value
68.68M
3-Year CAGR
24%
5-Year CAGR
27%
10-Year CAGR
29%
Castle Biosciences, Inc. Competitors Analysis of Total Current Liabilities
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Castle Biosciences, Inc. NASDAQ:CSTL | 68.68M | 12.9% | 22.5% | N/A | |
 DarioHealth Corp. NASDAQ:DRIO | 9.32M | -9.3% | -8.3% | 12.3% | |
 Fulgent Genetics, Inc. NASDAQ:FLGT | 84.97M | 5.2% | -4.2% | 37.3% | |
 Myriad Genetics, Inc. NASDAQ:MYGN | 133.80M | -5.0% | -8.1% | -4.7% | |
 Personalis, Inc. NASDAQ:PSNL | 39.63M | -5.7% | 4.8% | N/A | |
 Vir Biotechnology, Inc. NASDAQ:VIR | 92.81M | -19.1% | -22.9% | N/A | |
 AMN Healthcare Services, Inc. NYSE:AMN | 577.61M | -4.2% | -9.8% | 7.7% | |
 Evolent Health, Inc. NYSE:EVH | 385.26M | -17.0% | -2.9% | 11.3% | |
 CareDx, Inc NASDAQ:CDNA | 89.85M | 4.8% | 3.1% | 8.2% | |
 Geron Corporation NASDAQ:GERN | 111.54M | 1.1% | 19.6% | 30.4% | |
 Embecta Corp. NASDAQ:EMBC | 261.50M | -9.6% | 9.8% | N/A |
Castle Biosciences, Inc. Fair Value Envelope
Related Guides
Continue your CSTL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.